TRVI · Trevi Therapeutics, Inc.
$13.72
-0.19 (-1.37%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$2.05B
Shares
142.48M
Volume · Oct 5
1.72M
Avg daily vol (3M)
1.92M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.72
Open$13.97
Day$13.51–14.11
52W close$9.55–19.50
Avg vol 30d1.7M
Short int12.1M · 8.5% float · 8.8d
Short vol47%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$51.11M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$318.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.1%
Year over year · more shares
Price change (1Y)
+45.5%
Trailing year
Short interest
8.5%
Latest settlement · 8.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Trevi initiated the Phase 3 OCEAN-1 (IPF chronic cough) and Phase 2b LAKE (RCC) trials in Q2 2026, plans to initiate Phase 3 OCEAN-2 in Q3 2026, and ended Q2 with $318.9M in cash following an April financing of ~$162.3M net proceeds, extending runway into 2030; R&D spend rose to $15.2M and net loss widened to $17.8M.
Bullish
- + Initiated Phase 3 OCEAN-1 trial in IPF-related chronic cough in Q2 2026
- + April 2026 financing added ~$162.3M net proceeds; cash of $318.9M extends runway into 2030
- + Recent competitive exit positions Haduvio as a potential first-in-class therapy across all three chronic cough indications
- + JAMA publication of the Phase 2b CORAL trial and all six ATS 2026 submissions accepted, highlighting efficacy across cough frequencies
Bearish
- − Net loss widened to $17.8M in Q2 2026 from $12.3M in Q2 2025
- − LAKE trial SSRE in Q4 2026 could require sample-size increase of up to 50%
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
−18%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−2%
trailing
YTD return
+10%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Flat
1 of 221 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.47% of float · ▲ +0.5% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
221 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
EPS growth
+32%
Y/Y
Free cash flow
$-42.1M
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
−18%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Flat
1 of 221 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.47% of float · ▲ +0.5% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
221 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $14 · 42%
Range high $20
vs 200-day avg -4%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRVI
this stock
Trevi Therapeutics, Inc.
|
$2.05B | +9.6% | — | — | 8.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRVI | -4.7% | -20.5% | -2.3% | -4.2% | +9.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -5.9% | -21.1% | -13.9% | -5.8% | -4.0% |